Home Cart Sign in  
Chemical Structure| 1442472-39-0 Chemical Structure| 1442472-39-0

Structure of Ripretinib
CAS No.: 1442472-39-0

Chemical Structure| 1442472-39-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

DCC-2618 is a pan-KIT and PDGFRA inhibitor, and has antitumor activity.

Synonyms: DCC-2618

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ripretinib

CAS No. :1442472-39-0
Formula : C24H21BrFN5O2
M.W : 510.36
SMILES Code : O=C(NC1=CC=CC=C1)NC2=CC(C3=CC4=C(N(CC)C3=O)C=C(NC)N=C4)=C(Br)C=C2F
Synonyms :
DCC-2618
MDL No. :MFCD31657437
InChI Key :CEFJVGZHQAGLHS-UHFFFAOYSA-N
Pubchem ID :71584930

Safety of Ripretinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Ripretinib

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
M3 cells 16, 64, 256 nM 5 days Ripretinib in combination with MEKi (trametinib) also showed significant synergy in M3 cells, effectively inhibiting MPNST cell growth. PMC11565172
ST88-14 cells 16, 64, 256 nM 5 days Ripretinib in combination with MEKi (trametinib) significantly enhanced the inhibitory effect on MPNST cell growth and showed strong synergy. PMC11565172
OCCC spheroid cells 1–5 µM 7 days Ripretinib significantly enhanced the inhibitory effect of carboplatin on OCCC cell proliferation when co-cultured with CAFs PMC11149410
CAFs 1–5 µM 7 days Inhibited CAF survival and enhanced the inhibitory effect of carboplatin on OCCC cell proliferation PMC11149410
32D KITD816V cells 0.7 nM Evaluate the anti-proliferative effect of compound 54 on 32D KITD816V cells, showing a GI50 value of 0.7 nM. PMC9532533
32D KITD816V cells 1010 nM Evaluate the anti-proliferative effect of compound 13 on 32D KITD816V cells, showing a GI50 value of 1010 nM. PMC9532533
GIST-RPR 80 nM 24 h To investigate the effect of USP5 knockdown on GIST cell proliferation, results showed that USP5 knockdown reduced cell proliferation ability. PMC11425886
GIST-RPS 80 nM 24 h To investigate the effect of USP5 expression levels on GIST cell proliferation, results showed that USP5 overexpression increased cell proliferation ability. PMC11425886
AKP cells 1 μM Tested the response of AKP cells under growth-factor-poor conditions, confirming their growth dependence on KIT signaling PMC11078756

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CB17 SCID mice MPNST-2 PDX model Oral 25 mg/kg Once daily until the end of the experiment Ripretinib in combination with MEKi (trametinib) showed significant anti-tumor effects in the MPNST-2 PDX model, significantly inhibiting tumor growth and leading to tumor regression. PMC11565172
NOG mice OCCC xenograft model Oral 50 mg/kg Once daily for 28 days Ripretinib in combination with carboplatin significantly inhibited the growth of OCCC xenograft tumors PMC11149410
Mice 32D KITD816V xenograft mice model Oral 20, 40 mg/kg Twice daily for 12 days Evaluate the anti-tumor efficacy of compound 54 in the 32D KITD816V xenograft mice model, showing dose-dependent inhibition of tumor growth with TGI values of 45% and 71%. PMC9532533
Nude mice Subcutaneous xenograft model Oral 100 mg/kg Once daily until the end of the experiment To investigate the effect of USP5 overexpression and knockdown on tumor growth, results showed that USP5 overexpression promoted tumor growth, while USP5 knockdown reduced tumor growth. PMC11425886

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06619275 GIST - Gastrointestinal Stroma... More >>l Tumor Less << RECRUITING 2025-11-27 Praxis für interdisziplin?re O... More >>nkologie und H?matologie, Freiburg, Germany Less <<
NCT04282980 Gastrointestinal Stromal Tumor... More >>s Less << PHASE2 COMPLETED 2022-08-23 Beijing Cancer Hospital, Beiji... More >>ng, Beijing, China|Chinese People's Liberation Army General Hospital, Beijing, Beijing, China|Union Medical College Hospital, Chongqing Medical University, Chongqing, Chongqing, China|Union Medical College Hospital, Fujian Medical University, Fuzhou, Fujian, China|The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China|The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China|Fudan University Cancer Hospital, Shanghai, Shanghai, China|Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.96mL

0.39mL

0.20mL

9.80mL

1.96mL

0.98mL

19.59mL

3.92mL

1.96mL

 

Historical Records

Categories